{"version":"1.0","type":"link","title":"Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan.","author_name":"Pourjamal N 외","author_url":"https://prs-insight.online/author/Pourjamal%20N","provider_name":"PRSinsight","provider_url":"https://prs-insight.online","thumbnail_url":"https://prs-insight.online/og/paper/127802","thumbnail_width":1200,"thumbnail_height":630}